IONS — Ionis Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $13.42bn
- $13.84bn
- $943.71m
US FDA declines to approve higher-dose of Biogen's genetic disorder drug
U.S. STOCKS ON THE MOVE-Iron Mountain, Semler Scientific, Nvidia
U.S. STOCKS ON THE MOVE-GATX, Apple, Tesla
Ionis rises after neurological disorder drug shows promise in study
Ionis rises after rare neurological disorder drug shows promise in small study
Ionis' brain disorder drug shows promise in clinical trial (updated)
Ionis' brain disorder drug shows promise in clinical trial
Brief: Ionis announces positive topline results from pivotal study of zilganersen in Alexander disease
Brief: Biogen To Buy Alcyone Therapeutics, Expanding Drug Delivery Solutions For Key Products and Pipeline
Ionis, Arrowhead file dueling patent lawsuits over genetic-disorder drug
Brief: Arrowhead Pharmaceuticals Files Complaint For Declaratory Judgment Against Ionis Pharmaceuticals
U.S. STOCKS ON THE MOVE-Anavex Life Sciences, Oil companies, Yum! Brands
U.S. STOCKS ON THE MOVE-Anavex Life Sciences, oil companies, Yum Brands
Ionis Pharma up after FDA's 'breakthrough therapy' tag for neurological disease drug
U.S. STOCKS ON THE MOVE-Dick's Sporting Goods, Wix.com, NextDecade
U.S. STOCKS ON THE MOVE-CleanCore Solutions, Wolfspeed, UnitedHealth
Ionis Pharma up after FDA's 'breakthrough therapy' tag for neurological disease drug
Brief: Ionis Receives US FDA Breakthrough Therapy Designation For ION582 In Angelman Syndrome
U.S. RESEARCH ROUNDUP-Alphabet, Copart, Leidos